(Halifax) The Government of Canada is allocating approximately $ 4.8 million for a new national study that will examine the effects of a combination of approved COVID-19 vaccines in adults.
Researchers will look at the safety and effectiveness of the use of two different COVID-19 vaccines for the first and second doses.
The project will also study the effects of increasing the interval between doses.
The deAgain Joan Langley, a professor at Dalhousie University in Nova Scotia and co-head investigator of this research project, aims to determine the effects of various vaccine administration gaps on immunity and safety, in a context where questions are raised about the interchangeability of vaccines.
Researchers will also try to find out what the immune response is when two doses of different COVID-19 vaccine products are used and how long this reaction lasts.
The study, titled “Mixing the Second Doses of COVID-19 Vaccine for Safety and Immunogenicity” (MOSAIC), aims to recruit 1300 participants as soon as possible in Nova Scotia, Quebec, Ontario, Manitoba in Alberta and British Columbia.
Four COVID-19 vaccines are currently approved for use in Canada, three of which are distributed by public health programs: Pfizer-BioNotech, Modern and Oxford-AstraZeneca. As more vaccines become available, they will be added to the study to fill knowledge gaps in public health.
The research team says that the results of their work will be shared regularly with public health officials to help them make decisions for the continued deployment of vaccines in Canada.